ORIC Pharmaceuticals, Inc.
ORICNASDAQHealthcare● Active
$7.53
+$0.03(+0.40%)
Market Cap$779487242
P/E Ratio—
52W High$14.93
52W Low$7.23
ORIC Pharmaceuticals, Inc. (ORIC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ORIC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.34
Est. -$0.31 · -9.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS
ORIC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.36 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 4, 2026 | -$0.31 | -$0.34 | -9.7% | — | — | — |
| ▲ Q1 FY2026 | Feb 23, 2026 | -$0.34 | -$0.30 | +11.8% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.41 | -$0.33 | +19.5% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.46 | -$0.47 | -2.2% | — | — | — |
| ▲ Q2 FY2025 | May 5, 2025 | -$0.51 | -$0.42 | +17.6% | — | — | — |
| ▲ Q1 FY2025 | Feb 18, 2025 | -$0.52 | -$0.51 | +1.9% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.48 | -$0.49 | -2.1% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
-$0.34
EPS Est.
-$0.31
EPS Surpr.
-9.7%
Revenue
—
Q1 FY2026
Feb 23, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$0.34
EPS Surpr.
+11.8%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.41
EPS Surpr.
+19.5%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.47
EPS Est.
-$0.46
EPS Surpr.
-2.2%
Revenue
—
Q2 FY2025
May 5, 2025Beat
EPS Actual
-$0.42
EPS Est.
-$0.51
EPS Surpr.
+17.6%
Revenue
—
Q1 FY2025
Feb 18, 2025Beat
EPS Actual
-$0.51
EPS Est.
-$0.52
EPS Surpr.
+1.9%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.49
EPS Est.
-$0.48
EPS Surpr.
-2.1%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.39 | $-0.39 | $-0.39 | 3 |
| Q3 FY2027 | $-0.39 | $-0.39 | $-0.39 | 4 |
| Q2 FY2027 | $-0.38 | $-0.38 | $-0.38 | 3 |
| Q1 FY2027 | $-0.37 | $-0.37 | $-0.37 | 3 |
| Q4 FY2026 | $-0.38 | $-0.38 | $-0.38 | 7 |
| Q3 FY2026 | $-0.42 | $-0.37 | $-0.33 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -9.7% | $9.77 | $9.63 | -1.43% |
| ▲ Q1 FY2026 | Feb 23, 2026 | +11.8% | $11.11 | $11.71 | +5.40% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +19.5% | $12.48 | $12.19 | -2.32% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -2.2% | $9.20 | $9.52 | +3.48% |
| ▲ Q2 FY2025 | May 5, 2025 | +17.6% | $5.67 | $5.70 | +0.53% |
| ▲ Q1 FY2025 | Feb 18, 2025 | +1.9% | $8.36 | $7.85 | -6.10% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -2.1% | $10.30 | $10.26 | -0.39% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -7.1% | $8.39 | $8.28 | -1.31% |
Q2 FY2026-1.43%
Report Date
May 4, 2026
EPS Beat/Miss
-9.7%
Price Before
$9.77
Price After
$9.63
Q1 FY2026+5.40%
Report Date
Feb 23, 2026
EPS Beat/Miss
+11.8%
Price Before
$11.11
Price After
$11.71
Q4 FY2025-2.32%
Report Date
Nov 13, 2025
EPS Beat/Miss
+19.5%
Price Before
$12.48
Price After
$12.19
Q3 FY2025+3.48%
Report Date
Aug 12, 2025
EPS Beat/Miss
-2.2%
Price Before
$9.20
Price After
$9.52
Q2 FY2025+0.53%
Report Date
May 5, 2025
EPS Beat/Miss
+17.6%
Price Before
$5.67
Price After
$5.70
Q1 FY2025-6.10%
Report Date
Feb 18, 2025
EPS Beat/Miss
+1.9%
Price Before
$8.36
Price After
$7.85
Q4 FY2024-0.39%
Report Date
Nov 12, 2024
EPS Beat/Miss
-2.1%
Price Before
$10.30
Price After
$10.26
Q3 FY2024-1.31%
Report Date
Aug 12, 2024
EPS Beat/Miss
-7.1%
Price Before
$8.39
Price After
$8.28
Avg Beat Reaction-0.62%
Avg Miss Reaction+0.09%
Beat Rate4 / 8 quarters
Largest Move-6.10% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ORIC ends December
ORIC Pharmaceuticals, Inc. (ORIC) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.34 — missing the analyst consensus of $-0.31 by -9.7%. The next ORIC earnings date is expected around September 1, 2026.
Each quarter, investors track ORIC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ORIC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ORIC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ORIC earnings · 5 questionsORIC Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ORIC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ORIC historically reports after market close (AMC).
ORIC earnings datewhen is ORIC earningsORIC next earnings datewhen does ORIC report earningsORIC earnings calendar
▸ Source: FMP · ORIC Pharmaceuticals, Inc. SEC filings · US GAAP · ORIC Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026